Read our latest updates & insights

On 29 November 2024, Reuters reported that AstraZeneca and Daiichi Sankyo’s Enhertu® (trastazumab deruxtecan), will be added to China’s state-run health insurance scheme.  The addition of the drug, projected to be incorporated from early 2025, will aid in reducing the costs...

On 28 November 2024, Australia’s Pharmaceutical Benefits Scheme (PBS) published its agenda for the March 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting.  This follows the PBAC’s publication of its September 2024 intracycle meeting outcomes, which noted that,...

On 28 November 2024, each of Eisai and Biogen announced the launch of Leqembi® (lecanemab) in Korea for the treatment of adult patients with mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD dementia (early AD).  The product was approved by Korea’s Minist...

On 28 November 2024, Celltrion announced the commencement of global phase 3 clinical trials for CT-P44, biosimilar to Janssen’s Darzalex® (daratumumab), following submission of its global phase 3 clinical trial plan (IND) to the European Medicines Agency (EMA).  

Ear...

On 27 November 2024, BeiGene announced that the European Commission approved Tevimbra® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. ...

On 27 November 2024, Novo Nordisk Canada announced Canadian approval of Wegovy® (semaglutide)  for the reduction of risk of non-fatal myocardial infarction in adults with established cardiovascular disease.   

Wegovy® was approved in Canada for the treatment of obesi...

On 26 November 2024, CSPC Pharmaceutical Group Limited (CSPC) announced that its biologic license application for ustekinumab (biosimilar to Johnson & Johnson’s Stelara®) was accepted by the People’s Republic of China’s National Medical Products Administration (NM...

On 26 November 2024, Celltrion’s Omlyclo®, biosimilar to Genentech’s and Novartis’ Xolair® (omalizumab) was approved in Australia.  Omlyclo® is the first omalizumab biosimilar approved in Australia. 

Omylclo® was approved in Australia for two presentation...

On 26 November 2024, The Economic Times reported that AstraZeneca has received approval from India’s Central Drugs Standard Control Organisation (CSDCO) to market Lynparza® (olaparib) in India.  

The CDSCO granted approval for the use of Lynparza® in combinatio...

On 25 November 2024, GlaxoSmithKline (GSK) announced that the FDA has accepted its BLA for Blenrep® (belantamab mafodotin) in combination with BorDex (bortezomib plus dexamethasone) or PomDex (pomalidomide plus dexamethasone) for the treatment of patients with multiple myel...